Here's what we'll cover
Here's what we'll cover
If your child has been diagnosed with obesity and you have seen headlines about GLP-1 medications, you probably have a lot of questions. What is approved for kids? Is it safe? How do families get these treatments, and what do they cost?
Here is what the current approvals, research, and guidelines say, so you can have a well informed conversation with your child's doctor.
What the New Research Shows
A study published in Pediatrics in October 2026 by researchers at NYU looked at more than 3.5 million children aged 8 to 11 with obesity and without diabetes, using national health record data from 2019 to mid 2026. It found:
- GLP-1 prescribing in this age group rose about 310 fold over the study period.
- Even so, only about 0.6% of these children received a GLP-1 prescription.
- Children with obesity related conditions, older children, and girls were more likely to be prescribed one.
- Children with less social vulnerability were more likely to receive a prescription, raising questions about equal access.
The authors concluded that clinicians appear to be reserving these drugs mainly for children at the highest cardiometabolic risk.
Why Use Is Increasing
About 1 in 5 U.S. children and adolescents has obesity, according to the CDC. For many, lifestyle changes alone have not been enough. In 2023, the American Academy of Pediatrics clinical practice guideline said pediatricians should offer medication to adolescents 12 and older with obesity, alongside intensive health behavior and lifestyle treatment. The Pediatrics study authors note that guidelines also allow medication to be considered in children aged 8 to 11.
What Is FDA Approved for Children
Approvals differ by drug, age, and condition. Using a drug outside its approved age or condition is off label.
| Medication | Active ingredient | Approved pediatric use |
|---|---|---|
| Wegovy injection | Semaglutide | Chronic weight management, ages 12 and older |
| Saxenda | Liraglutide | Chronic weight management, ages 12 and older |
| Mounjaro | Tirzepatide | Type 2 diabetes, ages 10 and older |
| Victoza | Liraglutide | Type 2 diabetes, ages 10 and older |
| Ozempic | Semaglutide | Adults only |
| Zepbound | Tirzepatide | Adults only |
| Wegovy pill | Semaglutide | Adults only |
These approvals come from the current prescribing information for Wegovy, Saxenda, Mounjaro, Victoza, and Ozempic. No GLP-1 medication is FDA approved for weight management in children under 12, so prescribing in that group is off label and should involve a specialist.
What the Research Says About Safety and Results
Adolescents
In the STEP TEENS trial, adolescents aged 12 to 17 with obesity who took semaglutide 2.4 mg weekly saw an average 16.1% reduction in BMI over 68 weeks, compared with a 0.6% increase on placebo. Gastrointestinal side effects such as nausea, vomiting, and diarrhea were more common with semaglutide (62% vs. 42%), and 4% of teens on semaglutide developed gallstones versus none on placebo.
Younger Children
Data for children under 12 are much more limited, and long term effects across a full period of growth and development are not yet known. Trials in younger children are ongoing. That uncertainty is why specialist care and close monitoring matter.
What Doctors Monitor
- Growth in height, not just weight, and nutritional intake.
- Gastrointestinal side effects and hydration.
- Signs of gallbladder problems or pancreatitis, such as severe abdominal pain.
- Mood, eating behaviors, and body image.
- Blood sugar, blood pressure, cholesterol, and liver markers.
How Families Access Treatment
Most families start with their pediatrician, who may refer to a pediatric endocrinologist, an adolescent medicine specialist, or a children's hospital weight management program. Many academic centers offer multidisciplinary clinics that combine medical care, nutrition, and behavioral health.
Questions to Ask the Doctor
- Is my child's weight and health risk serious enough to consider medication now?
- Which medication would you recommend, and is it approved for my child's age?
- What monitoring schedule will we follow, and which side effects should we watch for?
- Is this expected to be long term treatment?
- What nutrition and behavioral support will go alongside the medication?
- Is my child eligible for any clinical trials?
Insurance and Cost
Coverage for children follows the same uneven patterns as for adults. Many commercial plans require prior authorization with documentation of BMI percentile, related conditions, and lifestyle treatment attempts. Medicaid coverage for obesity medications varies by state. For children under 12, coverage is especially hard to obtain because use is off label.
Manufacturer self pay programs have lowered some prices for families paying out of pocket, but options and eligibility vary by medication and age. Check GLP-1 coupons and savings programs and ask the specialist's office about assistance programs.
A Caution About Compounded Products
Compounded semaglutide and tirzepatide are not FDA approved, and the FDA has received hundreds of adverse event reports, some linked to dosing errors. Pediatric dosing requires precision, so most specialists advise against compounded GLP-1 products for children.
Medication Is One Part of the Plan
The AAP guideline emphasizes that medication should be used alongside, not instead of, intensive lifestyle and behavioral treatment. Research consistently shows children do better when the whole family takes part in healthy changes, so expect the care team to involve parents and siblings.
No waiting list. No insurance needed.
Frequently Asked Questions
Are GLP-1 medications FDA approved for children?
Some are. Wegovy injection and Saxenda are approved for weight management in adolescents 12 and older. Mounjaro and Victoza are approved for type 2 diabetes from age 10. None is approved for weight management under 12.
Is Ozempic approved for kids?
No. Ozempic is approved for adults with type 2 diabetes only. For adolescents with obesity, Wegovy injection is the approved semaglutide product.
How common are GLP-1 prescriptions in young children?
A 2026 Pediatrics study of more than 3.5 million children aged 8 to 11 with obesity found prescribing rose about 310 fold since 2019, but only about 0.6% received a GLP-1.
How well does semaglutide work in teenagers?
In the STEP TEENS trial, adolescents taking semaglutide 2.4 mg saw an average 16.1% reduction in BMI over 68 weeks, compared with a 0.6% increase on placebo.
What side effects should parents watch for?
Nausea, vomiting, diarrhea, and stomach pain are most common. Severe abdominal pain can signal gallbladder problems or pancreatitis and needs prompt medical attention.
Should children use compounded semaglutide?
Most specialists advise against it. Compounded GLP-1 products are not FDA approved, and the FDA has received adverse event reports, some tied to dosing errors.
The Bottom Line
GLP-1 prescribing for children aged 8 to 11 has risen sharply, about 310 fold since 2019, yet it remains uncommon, reaching about 0.6% of children with obesity. Wegovy and Saxenda are approved for weight management from age 12, Mounjaro and Victoza are approved for type 2 diabetes from age 10, and no GLP-1 is approved for weight management under 12.
If you are considering treatment for your child, start with your pediatrician, ask for a referral to a pediatric obesity specialist, and plan for medication to be one part of a family centered program with careful monitoring. To understand the medications and costs, explore GLP-1 coupons and savings programs, and for adults in your household who may be candidates, compare vetted telehealth providers. Always consult a qualified physician before starting, stopping, or adjusting any medication for your child.